← Shandong Dongyue Organosilicon Mat overview

Shandong Dongyue Organosilicon Mat vs Chemours: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shandong Dongyue Organosilicon Mat (300821.CS)

Q3 20263 Jul – 20 Aug 2026

▲3

Dongyue Silicone profit jumps 916% on higher prices, cheaper raw materials

First-half profit forecast up 905%-952% Dongyue Silicone told investors it expects first-half 2026 net profit of 424-444 million yuan, up roughly 905%-952% from a year earlier. The company credits higher silicone selling prices and cheaper raw materials, which fattened its gross margin. That is the core reason the stock is moving.
This is the first hard signal of the profit surge that drives the stock.
Actual interim report confirms 916% profit growth The final half-year report showed net profit of 429 million yuan, up 916%, on revenue of 2.665 billion yuan, up 14.5%. Second-quarter profit rose about 20% from the first quarter, so the improvement kept building through the period rather than fading. No dividend was declared.
It confirms the earlier forecast was real and shows momentum continued into Q2.
Silicone price upcycle lifts the whole chemical sector Several chemical and materials companies reported huge profit jumps in the same period, pointing to a broad rise in product prices and easing raw-material costs. For Dongyue, this means the profit boost is not a one-off company quirk but part of an industry pricing cycle that can persist.
It shows the profit driver is industry-wide, not a one-time event.
No dividend and one-off gains temper the good news The company will pay no cash dividend, and about 41 million yuan of the profit came from one-off items like asset sales, not core operations. So while the headline growth is real, part of it is not repeatable, and shareholders get no cash back this half.
It is the main counterweight investors should weigh against the strong headline.

July 20263 Jul – 20 Aug 2026

▲3

Dongyue Silicone profit jumps 916% on higher prices, cheaper raw materials

First-half profit forecast up 905%-952% Dongyue Silicone told investors it expects first-half 2026 net profit of 424-444 million yuan, up roughly 905%-952% from a year earlier. The company credits higher silicone selling prices and cheaper raw materials, which fattened its gross margin. That is the core reason the stock is moving.
This is the first hard signal of the profit surge that drives the stock.
Actual interim report confirms 916% profit growth The final half-year report showed net profit of 429 million yuan, up 916%, on revenue of 2.665 billion yuan, up 14.5%. Second-quarter profit rose about 20% from the first quarter, so the improvement kept building through the period rather than fading. No dividend was declared.
It confirms the earlier forecast was real and shows momentum continued into Q2.
Silicone price upcycle lifts the whole chemical sector Several chemical and materials companies reported huge profit jumps in the same period, pointing to a broad rise in product prices and easing raw-material costs. For Dongyue, this means the profit boost is not a one-off company quirk but part of an industry pricing cycle that can persist.
It shows the profit driver is industry-wide, not a one-time event.
No dividend and one-off gains temper the good news The company will pay no cash dividend, and about 41 million yuan of the profit came from one-off items like asset sales, not core operations. So while the headline growth is real, part of it is not repeatable, and shareholders get no cash back this half.
It is the main counterweight investors should weigh against the strong headline.

Latest3 Jul – 20 Aug 2026

▲3

Dongyue Silicone profit jumps 916% on higher prices, cheaper raw materials

First-half profit forecast up 905%-952% Dongyue Silicone told investors it expects first-half 2026 net profit of 424-444 million yuan, up roughly 905%-952% from a year earlier. The company credits higher silicone selling prices and cheaper raw materials, which fattened its gross margin. That is the core reason the stock is moving.
This is the first hard signal of the profit surge that drives the stock.
Actual interim report confirms 916% profit growth The final half-year report showed net profit of 429 million yuan, up 916%, on revenue of 2.665 billion yuan, up 14.5%. Second-quarter profit rose about 20% from the first quarter, so the improvement kept building through the period rather than fading. No dividend was declared.
It confirms the earlier forecast was real and shows momentum continued into Q2.
Silicone price upcycle lifts the whole chemical sector Several chemical and materials companies reported huge profit jumps in the same period, pointing to a broad rise in product prices and easing raw-material costs. For Dongyue, this means the profit boost is not a one-off company quirk but part of an industry pricing cycle that can persist.
It shows the profit driver is industry-wide, not a one-time event.
No dividend and one-off gains temper the good news The company will pay no cash dividend, and about 41 million yuan of the profit came from one-off items like asset sales, not core operations. So while the headline growth is real, part of it is not repeatable, and shareholders get no cash back this half.
It is the main counterweight investors should weigh against the strong headline.

Chemours Co (CC)

Q3 202624 Jun – 7 Aug 2026

▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.
This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.
New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.
It introduces a new legal threat that could increase costs and uncertainty for CC.
2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.
It provides a forward-looking financial picture that directly influences CC's valuation.
Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.
It finalizes a major liability that affects CC's financial obligations and investor sentiment.

July 202624 Jun – 7 Aug 2026

▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.
This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.
New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.
It introduces a new legal threat that could increase costs and uncertainty for CC.
2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.
It provides a forward-looking financial picture that directly influences CC's valuation.
Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.
It finalizes a major liability that affects CC's financial obligations and investor sentiment.

Latest24 Jun – 7 Aug 2026

▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.
This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.
New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.
It introduces a new legal threat that could increase costs and uncertainty for CC.
2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.
It provides a forward-looking financial picture that directly influences CC's valuation.
Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.
It finalizes a major liability that affects CC's financial obligations and investor sentiment.